Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 7/20 | 0.65 |
| ▸ | NPY1R | P25929 | 3/20 | 0.60 |
| ▸ | NPY2R | P49146 | 3/20 | 0.60 |
| ▸ | NPY4R | P50391 | 3/20 | 0.60 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.57 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.56 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641067 | 1.00 | GHSR (0.65) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29641169 | 1.00 | GHSR (0.65) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL30169478 | 1.00 | GHSR (0.65) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29641171 | 0.98 | GHSR (0.68) | GHSR | |
| SCHEMBL29672136 | 0.96 | NPY4R (0.62) | GHSRNPY1RNPY2RNPY4RKISS1R | |
| SCHEMBL29641180 | 0.96 | GHSR (0.58) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL30118086 | 0.95 | GHSR (0.57) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL30773914 | 0.95 | GHSR (0.57) | GHSRNPY1RNPY2RNPY4RUTS2R | |
| SCHEMBL29419958 | 0.95 | GHSR (0.61) | GHSRNPY1RNPY2RNPY4R | |
| SCHEMBL22133204 | 0.94 | NPY1R (0.59) | GHSRNPY1RNPY2RNPY4RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250002531-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-01-02 | — | — | US | disclosed |
| US-20250002530-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-01-02 | — | — | US | disclosed |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-10-24 | — | — | US | disclosed |
| US-12065511-B2 | Aromatic-cationic peptides and uses of same | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4233887-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4085920-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-4000690-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | Stealth BioTherapeutics Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002531-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | ADM2, VIP, PEPD | GHSR 944/4885NPY1R 140/4885NPY2R 76/4885 |
| US-20250002530-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | ARG2, OAT, PDF | GHSR 3816/4885NPY1R 756/4885NPY2R 633/4885 |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | GHSR 1981/4885NPY1R 2251/4885NPY2R 2584/4885 |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | MTPN, CKMT1A; CKMT1B, TFAM | GHSR 4526/4885NPY1R 3326/4885NPY2R 3526/4885 |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | GHSR 944/4885NPY1R 140/4885NPY2R 76/4885 |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | GHSR 1981/4885NPY1R 2251/4885NPY2R 2584/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | GHSR 2407/4885NPY1R 1155/4885NPY2R 1797/4885 |
| US-12065511-B2 | Aromatic-cationic peptides and uses of same | ARG2, OAT, PDF | GHSR 3816/4885NPY1R 756/4885NPY2R 633/4885 |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | CRYAA, CRYAB, PRPH | GHSR 947/4885NPY1R 534/4885NPY2R 576/4885 |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | GHSR 4838/4885NPY1R 4818/4885NPY2R 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.